Survival improvement in hormone-responsive young breast cancer patients with endocrine therapy.

HR-positive young breast cancer patients have a poorer survival compared with older patients, even with more frequent chemotherapy, but more recent use of tamoxifen and ovarian suppression might improve this outcome in these patients.